Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lea Beltzig

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Frontiers in Oncology|July 5, 2022
Temozolomide - Just a Radiosensitizer?Bernd Kaina, Lea Beltzig, Herwig Strik
Cancers|December 24, 2021
Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma CellsLea Beltzig, Björn Stratenwerth, Bernd Kaina
Cells|August 26, 2022
Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for SenolyticsLea Beltzig, Markus Christmann, Bernd Kaina
Nutrients|August 10, 2021
Cytotoxic, Genotoxic and Senolytic Potential of Native and Micellar CurcuminLea Beltzig, Anna Frumkina, Christian Schwarzenbach, et al.
Anticancer Research|February 29, 2024
Genotoxic and Cytotoxic Activity of Fisetin on Glioblastoma CellsLea Beltzig, Markus Christmann, Minodora Dobreanu, et al.
International Journal of Molecular Sciences|September 26, 2020
Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma CellsBernd Kaina, Lea Beltzig, Andrea Piee-Staffa, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|March 24, 2025
Apoptotic and senolytic effects of hERG/Eag1 channel blockers in combination with temozolomide in human glioblastoma cellsBodo Haas, Inken Roth, Luisa Säcker, et al.
Molecular Cancer Therapeutics|July 13, 2021
Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold DosesBjörn Stratenwerth, Susanne M Geisen, Yang He, et al.
Cancers|July 24, 2021
Targeting c-IAP1, c-IAP2, and Bcl-2 Eliminates Senescent Glioblastoma Cells Following Temozolomide TreatmentChristian Schwarzenbach, Larissa Tatsch, Juliana Brandstetter Vilar, et al.
Cancers|May 14, 2022
Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma CellsLea Beltzig, Christian Schwarzenbach, Petra Leukel, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Frontiers in Oncology|July 5, 2022
Temozolomide - Just a Radiosensitizer?Bernd Kaina, Lea Beltzig, Herwig Strik
Cancers|December 24, 2021
Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma CellsLea Beltzig, Björn Stratenwerth, Bernd Kaina
Cells|August 26, 2022
Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for SenolyticsLea Beltzig, Markus Christmann, Bernd Kaina
Nutrients|August 10, 2021
Cytotoxic, Genotoxic and Senolytic Potential of Native and Micellar CurcuminLea Beltzig, Anna Frumkina, Christian Schwarzenbach, et al.
Anticancer Research|February 29, 2024
Genotoxic and Cytotoxic Activity of Fisetin on Glioblastoma CellsLea Beltzig, Markus Christmann, Minodora Dobreanu, et al.
International Journal of Molecular Sciences|September 26, 2020
Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma CellsBernd Kaina, Lea Beltzig, Andrea Piee-Staffa, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|March 24, 2025
Apoptotic and senolytic effects of hERG/Eag1 channel blockers in combination with temozolomide in human glioblastoma cellsBodo Haas, Inken Roth, Luisa Säcker, et al.
Molecular Cancer Therapeutics|July 13, 2021
Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold DosesBjörn Stratenwerth, Susanne M Geisen, Yang He, et al.
Cancers|July 24, 2021
Targeting c-IAP1, c-IAP2, and Bcl-2 Eliminates Senescent Glioblastoma Cells Following Temozolomide TreatmentChristian Schwarzenbach, Larissa Tatsch, Juliana Brandstetter Vilar, et al.
Cancers|May 14, 2022
Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma CellsLea Beltzig, Christian Schwarzenbach, Petra Leukel, et al.
Pageof 1